MHRA suspends COX-2 licence

GPs must stop prescribing the painkiller lumiracoxib (Prexige) and switch patients to an alternative drug, says the Medicines and Healthcare products Regulatory Agency (MHRA).

Concerns over liver damage caused by the COX-2 inhibitor has led to suspension of the drug's UK licence by the MHRA.

It follows similar moves by Australia, New Zealand, the US and Canada earlier this year.

Data has shown an increase in the number of serious liver reactions with the licensed 100mg dose, some of which occurred within one month of use.

The drug was licensed for pain relief in osteoarthritis of the knee and hip and has been available in the UK since December 2005.

Between October 2006 and September 2007 around 5,000 UK patients were given one or more scrips for the drug.

Up to 13 November, the MHRA received 23 reports of severe adverse reactions, three of which were liver reactions.

In August, the MHRA said the drug must be contraindicated in patients with a history of liver problems.

But after closer examination, the MHRA's Committee on the Safety of Human Medicines ruled that 'previous measures could not be relied upon to guarantee patient safety'.

The finding adds to concerns about COX-2 inhibitors.

A spokeswoman for manufacturer Novartis advised GPs to make appointments for patients as soon as convenient to discuss switching to an alternative drug.

'Novartis continues to believe Prexige is an important treatment option,' she added.

Dr Bill Beeby, chairman of the GPC prescribing sub-committee, said: 'No single drug can be recommended as a substitution.'

rachel.liddle@haymarket.com

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pension tax solution for judges shows government could do more for doctors, says BMA

Pension tax solution for judges shows government could do more for doctors, says BMA

Government plans to 'effectively exempt judges from pension tax' show the government...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Second-phase COVID-19 vaccine rollout maintains prioritisation by age

Second-phase COVID-19 vaccine rollout maintains prioritisation by age

The Joint Committee on Vaccination and Immunisation (JCVI) has published advice on...

PCNs paid £70m for first-wave COVID-19 jab campaign as NHS plots next phase of rollout

PCNs paid £70m for first-wave COVID-19 jab campaign as NHS plots next phase of rollout

Primary care network (PCN) COVID-19 vaccination sites have been paid £70m this month...

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP Dr Farzana Hussain is personally telephoning scores of patients who have...

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Almost half of people who experienced potential cancer symptoms in the first wave...